|
![]() |
|
|
Ranitidine
drug data and news
Ranitidine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Ranitidine | ||
| Brand Names/Synonyms | Achedos; Acidex; Atural; Axoban; Coralen; Curan; Duractin; Ezopta; Gastrial; Gastrosedol; HSDB 3925; Istomar; Logast; Mauran; Melfax; Microtid; Noctone; Ptinolin; Quantor; Quicran; RND; Radinat; Randin; Raniben; Ranidine; Ranin; Raniogas; Raniplex; Ranisen; Raniter; Ranitidina [Inn-Spanish]; Ranitidine; Ranitidine Base; Ranitidine Hcl; Ranitidine Hydrochloride; Ranitidine [Usan:Ban:Inn]; Ranitidinum [Inn-Latin]; Ranitiget; Rantacid; Rantidine; Rantidine Hcl; Ratic; Raticina; Sampep; Sostril; Taural; Terposen; Trigger; Tritec; Ul-Pep; Ulceranin; Ulcex; Ultidine; Urantac; Verlost; Vesyca; Vizerul; Weichilin; Weidos; Xanidine; ZANTAC; Zantab; Zantac; Zantac 150; Zantac 75; Zantac in Plastic Container; Zantadin; Zantic; [Inn-Latin] | ||
| Indication | For the treatment of peptic or duodenal ulcers | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Ranitidine, a histamine H2-receptor antagonist similar to cimetidine and famotidine, is used to treat gastrointestinal disorders such as Helicobacter pylori-related peptic ulcer disease. | ||
| Mechanism Of Action | Ranitidine competes with histamine for binding at H2 receptors on gastric parietal cells. Competitive inhibition results in reduced basal and nocturnal gastric acid secretion. Ranitidine also decreases the amount of gastric acid released in response to stimuli such as food, caffeine, insulin, betazole, or pentagastrin. Other actions of ranitidine include an increase in gastric bacterial flora such as nitrate-reducing organisms. | ||
| Ranitidine News (When available) |
Omnicare Adjusts Q1 Profit To Include Special Charge - Update May 10, 2006 Omnicare Files 2006 First Quarter 10-Q; Updates First Quarter ... May 10, 2006 Omnicare allocates litigation funds May 11, 2006 Wockhardt to expand India operations May 1, 2006 Omnicare takes $24M charge May 11, 2006 Clinical: Tiredness, aspirin and PPIs May 10, 2006 Off-Label Drug Use May 2, 2006 NSAIDs: Pain Relief or Pain in the Gut? May 2, 2006 SCS Capital to help fund Nanopharm project Apr 30, 2006 Wockhardt Q1 net loss at Rs 3.7 cr Apr 25, 2006 State sues over high prescription drug prices Apr 28, 2006 Indigestion defined Apr 29, 2006 Wockhardt reports net loss of Rs37mn Apr 26, 2006 | ||
| Dosage Forms | CAPSULE; LIQUID; SOLUTION; TABLET | ||
| Drug_Category | Anti-ulcer Agents; Histamine Antagonists; ATC:A02BA02; ATC:A02BA07 | ||
| Absorption | 50% absorbed after oral administration | ||
| Interactions |
Interactions for Ranitidine: Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). Coadministration with aspirin results in a slight decrease in the rate of salicylate absorption that is clinically unimportant. Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from TRITEC. These effects are clinically insignificant. For information on drug interactions associated with ranitidine, refer to the ZANTAC ® package insert. | ||
| Toxicity | muscular tremors, vomiting, and rapid respiration, LD50=77mg/kg (orally in mice) | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | N'-[2-[[5-(dimethylaminomethyl)-2-furyl]methylsulfanyl]ethyl]-N-methyl-2-nitro-ethene-1,1-diamine | ||
| Chemical Formula | C13H22N4O3S | ||
| Molecular Weight | 314.405 g/mol | ||
| Smiles String | CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C | ||
| Melting Point | 69-70 °C | ||
| Water Solubility | 24.7 mg/mL | ||
| State | Solid, a white to pale yellow, granular substance | ||
| LogP/Hphobicity | 1.93 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Primarily Hepatic, Ranitidine is metabolized to the N-oxide, S-oxide, and N-desmethyl metabolites | ||
| Half Life | 2.8-3.1 hours | ||
| Protein Binding [%] | 15% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Ranitidine.html http://www.rxlist.com/cgi/generic2/ranitbc.htm http://www.pharmgkb.org/views/index.jsp?objId= | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00254 | ||
| CAS Registry Number | 66357-35-5 | ||
| KEGG Compound ID | C07233 | ||
| PubChem ID | SID:187111 | ||
| PharmGKB ID | PA451224 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2243038 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |